Standard-Dose vs. High-Dose Chemoradiotherapy With, Without Cetuximab for Lung Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal The Lancet Oncology, researchers have found that high-dose conformal radiotherapy with concurrent chemotherapy was not better than standard-dose radiotherapy with concurrent radiotherapy for the treatment of patients with stage 3 non-small cell lung cancer (NSCLC), and might actually be harmful to patients.

For the international, open-label, two-by-two factorial phase 3 study, researchers randomly assigned 166 patients to receive standard-dose radiation plus carboplatin and paclitaxel, 121 to high-dose radiation plus chemotherapy, 147 to standard-dose radiotherapy with chemotherapy and cetuximab, and 110 patients to high-dose chemoradiotherapy plus cetuximab.

Results showed a median overall survival of 28.7 months (95% CI: 24.1 - 36.9) for the standard-dose radiotherapy group compared with 20.3 months (95% CI: 17.7 - 25.0) for the high-dose radiotherapy group (HR = 1.38; 95% CI: 1.09 - 1.76; P = 0.004).

Median overall survival for those who received chemoradiotherapy plus cetuximab was 25.0 (95% CI: 20.2 - 30.5) versus 24.0 months (95% CI: 19.8 - 28.6) for those who did not receive cetuximab (HR = 1.07; 95% CI: 0.84 - 1.35).

In regard to safety, there were more treatment-related deaths in the high-dose radiation plus chemotherapy and cetuximab groups, and cetuximab treatment was associated with a higher incidence of severe adverse events (P < 0.0001).

The findings suggest that high-dose chemoradiotherapy is no better than standard-dose for patients with stage 3 NSCLC, and the addition of cetuximab to chemoradiotherapy provides no benefit in overall survival.

Mesothelioma: No Cure Yet, But Much Promise in New Therapies
High-dose radiotherapy was not better than standard-dose for NSCLC.
The authors aimed to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to concurrent chemoradiation for patients with inoperable stage III non-small-cell lung cancer.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs